The Centers for Medicare and Medicaid Services appear to be anticipating much stronger near-term uptake of Eisai Co., Ltd. and Biogen, Inc.’s Leqembi (lecanemab-irmb) for Alzheimer's disease than the companies do, based on a forecast recently disclosed by the agency.
Key Takeaways
-
Medicare Part B spending on Leqembi for Alzheimer’s will total $3.5bn in 2025, according to CMS.
CMS expects Medicare Part B spending on Leqembi will reach approximately $3.5bn in 2025 across the fee-for-service and Medicare Advantage...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?